WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer Celebrates 5 Years of High-Impact Corporate Volunteer Missions 16 June 2008
Pfizer Completes Acquisition of Encysive Pharmaceuticals Inc. 12 June 2008
High Dose Lipitor Can Reduce the Risk of Cardiovascular Events in Bypass Surgery Patients 22 May 2008
Pfiser's List of Grants and Charitable Contributions 15 May 2008
Esperion Therapeutics Completes $22.75 M Series A Financing 01 May 2008
Pfizer Enters into Research Consortium to Expand Understanding of Diabetes and Obesity Pathobiology 26 April 2008
Pfizer Reports First-Quarter 2008 Results 18 April 2008
Lipitor Provided an Unexpectedly Potent Heart Benefit 02 April 2008
Pfizer Successfully Completes Tender Offer for Shares of Encysive Pharmaceuticals Inc. 02 April 2008
Federal Court of Appeal in Canada Upholds Lipitor Enantiomer Patent 21 March 2008
Pfizer Wins Challenge to Two Main U.S. Patents for Celebrex 07 March 2008
Pfizer Presents New Opportunities for Global Growth 06 March 2008
Pfizer to Acquire Serenex to Extend Oncology Pipeline 03 March 2008
Pfizer Voluntarily Withdraws Lipitor Advertising Featuring Dr. Robert Jarvik 25 February 2008
Pfizer Reports Fourth-Quarter and Full-Year 2007 Results 24 January 2008
Pfizer and Scil Finalize Agreement for Novel Cartilage Growth Factor 17 January 2008
Pfizer Wins Key New York State Court Ruling on Celebrex 11 January 2008
Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate 07 January 2008
Pfizer Completes Sale of Consumer Healthcare Business 21 December 2007
Pfizer to Acquire CovX to Extend Biotherapeutics Investment 19 December 2007
  • Start
  • Prev
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • Next
  • End

Business & Industry

  • Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma

Research & Development

  • Candidate found to inhibit malignant melanoma growth
  • A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA approves first over-the-counter naloxone nasal spray
  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer invests $43 billion to battle cancer

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.